Uremia Maintenance Hemodialysis
Conditions
Interventions
Traditional Treatment Group:Correcting hyperphosphatemia with calcium containing or non calcium containing phosphate binders, and controlling secondary hyperparathyroidism with cinacalcet hydrochlorid
New treatment group:On the basis of traditional treatment, an additional 800IU of vitamin D3 capsules were taken orally daily, and 60mg of denosumab was injected subcutaneously every 6 months for a to
Sponsors
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 75 years, gender unrestricted. 2. Diagnosis of CKD stage 5 according to the 2012 KDIGO guidelines (eGFR<=15 ml/(ml/min/1.73m²)); 3. Receiving regular hemodialysis treatment 2-3 times per week, each session lasting 4 hours, for more than 3 months. 4. Serum parathyroid hormone (iPTH) = 400 pg/ml, and dual-energy X-ray absorptiometry (DXA) indicates bone mass reduction or osteoporosis. 5.Signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who have severe bleeding tendency and active bleeding, or have clear coagulation dysfunction; 2. Lactating or pregnant women or those who plan to become pregnant within one year; 3. Those who have undergone parathyroidectomy within 1 year; 4. History of infection, malignant tumor, active rheumatic immune disease; 5. Patients with an expected survival of less than one year; 6. As judged by the investigator, the patient has other conditions that are not suitable for enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vascular Calcification Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| AAAAll-cause death; | — |
Countries
China
Contacts
Public ContactYang Guang
The First Affiliated Hospital of Nanjing Medical University (Jiangsu Province Hospital)
Outcome results
None listed